Figure 1.
SLFN11 depletion by siRNA reverses cisplatin sensitivity in FANCD2 deficient PD20 cells. (A) SLFN11 expression in human cell lines as determined by western blotting. (B) SLFN11 expression in PD20 cells treated with siSLFN11#1 and #2. siLuc, siLuciferase. (C) Cell survival assay of PD20 and PD20 complemented with FANCD2. Cells were treated with 2 different siSLFN11. Means ± standard error of the mean (SEM) of 3 independent experiments are shown. (D) Cell cycle profile. Cells were transfected with siRNA oligos and 48 hours later treated with 10 ng/mL MMC for an additional 24 hours. Cells were then fixed in 70% ethanol, stained with anti-BrdU and PI, and analyzed using a FACS Canto II flow cytometer (BD Biosciences).

SLFN11 depletion by siRNA reverses cisplatin sensitivity in FANCD2 deficient PD20 cells. (A) SLFN11 expression in human cell lines as determined by western blotting. (B) SLFN11 expression in PD20 cells treated with siSLFN11#1 and #2. siLuc, siLuciferase. (C) Cell survival assay of PD20 and PD20 complemented with FANCD2. Cells were treated with 2 different siSLFN11. Means ± standard error of the mean (SEM) of 3 independent experiments are shown. (D) Cell cycle profile. Cells were transfected with siRNA oligos and 48 hours later treated with 10 ng/mL MMC for an additional 24 hours. Cells were then fixed in 70% ethanol, stained with anti-BrdU and PI, and analyzed using a FACS Canto II flow cytometer (BD Biosciences).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal